Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

Carboplatin

For research use only.

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

62 publications

Carboplatin Chemical Structure

CAS No. 41575-94-4

Carboplatin (JM-8, CBDCA, NSC 241240) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Carboplatin has been cited by 62 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Carboplatin (JM-8, CBDCA, NSC 241240) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[6]
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  NGDHbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOyMVI26oDLzszN M4SwU|czKGh? M1fvVYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MlHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{exNFUoRjJ4MUO3NVA2RC:jPh?=
Tca8113/CBP  M3\YOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S3dFIuOjYkgJpOwG0> M{DvWlczKGh? MmjlbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NGHCXlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|ExPSd-Mk[xN|cyODV:L3G+
Tca8113/PYM  MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TlZlIuOjYkgJpOwG0> NIfifYQ4OiCq NEfHRW1qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{exNFUoRjJ4MUO3NVA2RC:jPh?=
SKOV3 NF22VFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nTRlYxKG2pL33s MUOxMVUh\A>? NF7mfmxqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTD0bY1mKGSncHXu[IVvfGy7 Ml\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{ewOFMoRjJ4MUO3NFQ{RC:jPh?=
SKOV3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTxNE01KM7:Zz;tcC=> MoLQNlQwPDhxN{KgbC=> NY\1Wm1HcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NEnERmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOVI4Oyd-Mk[xNlUzPzN:L3G+
SKOV3 MlvQRZBweHSxc3nzJGF{e2G7 NFft[nEzKM7:Zz;tcC=> NUTj[4g2PDhiaB?= MlTObY5lfWOnczDhdI9xfG:|aYO= NYDvVXhrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlUzPzNpPkK2NVI2Ojd|PD;hQi=>
OSA M4m2NmNtd26xZ3XubYMhSXO|YYm= M2\zd|IvPS93IN88US=> NYr1eXJoemW|dXz0d{BqdiCub4fldkBkd2yxbomg[o9zdWG2aX;uJIF{KGOxbYDhdoVlKHSxIHXpeIhmeiCETVmxJJNqWk6DIITy[YF1dWWwdB?= M{XGdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUGwOlIxLz5{NkGxNFYzODxxYU6=
A549 M4TMR2Z2[3Srb36gRZN{[Xl? NVnKTJN6OC9{NT:1NEDPxE1? NV7GWVhOOjRiaB?= Mlvz[I94dnKnZ4XsZZRmeyCvaWKtNlA2KGW6cILld5Nqd28EoB?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975 NWrNW2VrTnWldHnvckBCe3OjeR?= NGX1c3UxNzJ3L{WwJO69VQ>? MXOyOEBp NHHWcFlld3ewcnXneYxifGW|IH3pVk0zODViZYjwdoV{e2mxbtMg MnvQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N|E4RC:jPh?=
A549 MVnGeYN1cW:wIFHzd4F6 Ml:1NE8zPS93MDFOwG0> MYqyOEBp MWf1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44> MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975 MluxSpVkfGmxbjDBd5NigQ>? MXuwM|I2NzVyIN88US=> MYmyOEBp NWDZbpU{fXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w NH;UfI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO|MyPyd-MkW5NVc{OTd:L3G+
A549 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPESGJbOjVizszN NHPDXFEzPCCq M1LzcolvcGmkaYTzJINmdGxiZ4Lve5Rp MnrZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N|E4RC:jPh?=
H1975 NHHSTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfOOmYzPSEQvF2= NHXSc5ozPCCq MlPkbY5pcWKrdIOgZ4VtdCCpcn;3eIg> Mn7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N|E4RC:jPh?=
MDA-MB-231 M4rwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mki5NE0zOjBizsznM41t NHizVok4OiCq NWn2eIFTUUN3MNMgQUA5PiEQvF2= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh|N{[5NUc,OjV6M{e2PVE9N2F-
T47D M1O0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXxOHdNOC1{MkCg{txoN22u M3P1T|czKGh? M{i4S2lEPTEEoE2gOFgvQSEQvF2= NG\UT4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizO|Y6OSd-MkW4N|c3QTF:L3G+
LCTCC NUjzO2c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNwOPMAjeK2VQ>? NFf4XJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N|E3Pyd-MkW3O|MyPjd:L3G+
MCTCC NFvvb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJwOPMAjeK2VQ>? NFfOWHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N|E3Pyd-MkW3O|MyPjd:L3G+
MegTCC NFPz[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvubmtKSzVyPUSuNgKBkcL3TR?= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MonoTCC NVfTd3dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHy2c4hKSzVyPUWuOwKBkcL3TR?= M4naeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{ezNVY4Lz5{NUe3N|E3PzxxYU6=
MCF7 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDJ[4QzOCEQvF2= NX;5OZF2PzJiaB?= MULpcoR2[2W|IHPlcIwh\GWjdHigc4YhUFBzzsKt[IVxdGW2ZXSgUWNHPyClZXzsdy=> NXTY[nJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlkxOjVpPkK1O|Y6ODJ3PD;hQi=>
A-549  M3WyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH1NE42KM7:TR?= Mm\XNlQhcA>? NH\iclVFVVORwrC= MnSybY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NYr5dXBORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVU3QTBpPkK1O|U2PjlyPD;hQi=>
A-549  NYnNb2t5SXCxcITvd4l{KEG|c3H5 MV[wMlUh|ryP M2fUNVQ5KGh? M{LxTmROW00EoB?= M3XzV5Npd3e|IHXhdox6KGGyb4D0c5NqeyCoZXH0eZJmeyCrbnPseYRqdmdiYnzlZoJqdmdiYX7kJINpem:vYYTpckBkd26mZX7zZZRqd25? NHHVbmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1OVY6OCd-MkW3OVU3QTB:L3G+
A-549  MYDGeYN1cW:wIFHzd4F6 M1zMTlAvPSEQvF2= M16xWFQ5KGh? M3zBN2ROW00EoB?= NW[xVYlPe2ixd4OgZYJmenKjboSgcYlkem:2dXL1cIUh\Gm|coXweIlwdg>? NUS0VnNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVU3QTBpPkK1O|U2PjlyPD;hQi=>
A-549  M{HycmZ2[3Srb36gRZN{[Xl? NXvMdnFFOC53IN88US=> MnnyOFghcA>? NIDTR5VFVVORwrC= NEHrOZNqdmirYnn0d{Bw\iClZXzsJI1q\3KjdHnvcuKh MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NU[5NEc,OjV5NUW2PVA9N2F-
RMG-1 M2\BRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHiXZpKSzVyPUK4MlghyrFiMz62JI1oN0x? NVmxVIFNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlY6OTNpPkK1O|I3QTF|PD;hQi=>
FN-RMG-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPqTWM2OD12MD61JOKyKDRwMjDt[{9NEiEQvF2= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{NkmxN{c,OjV5Mk[5NVM9N2F-
RMG-1-hFUT NYTUbGhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvZc21KSzVyPUW4MlEhyrFiMj60JI1oN0x? MnnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
FN-RMG-1-hFUT M1TDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTFzOD64JOKyKDF|LkigcYcwVA>? M1X5SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K2PVE{Lz5{NUeyOlkyOzxxYU6=
CHP-134  MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j3[|Eh|ryP MUjEUXNQyqB? NEHPS|BqdmirYnn0d{B{cWewaX\pZ4FvfCClZXzsJIdzd3e2aDDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OES2N{c,OjV4NUi0OlM9N2F-
IMR-32 NGLXSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrkNUDPxE1? MYHEUXNQyqB? NUK0foducW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OES2N{c,OjV4NUi0OlM9N2F-
CHP-134  NGPtb5RHfWO2aX;uJGF{e2G7 M1joe|ExKM7:TdMg Mn;WSG1UV8Li Moe1bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> M2HIRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW4OFY{Lz5{NU[1PFQ3OzxxYU6=
IMR-32 MkPDSpVkfGmxbjDBd5NigQ>? MmXzNVAh|ryPwrC= NEnQXIhFVVORwrC= MWXpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigS3NMOjh|MEO3NS=> M1zuOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW4OFY{Lz5{NU[1PFQ3OzxxYU6=
A549 NV3U[4o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn1PZExNjJvNECwNEDPxE1? MknYO|IhcA>? NWfpOJBvUUN3ME2xNlYhyrFiNT6wJO69VQ>? M2jBbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1NlQ{Lz5{NU[yOVI1OzxxYU6=
A549/CDDP NXu4XY9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXORZkxNjJvNECwNEDPxE1? MWO3NkBp NInGfWlKSzVyPUK0NOKhyrIEoES1Mlch|ryP NUHCN2JERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlUzPDNpPkK1OlI2OjR|PD;hQi=>
H460  M1XCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPCbWYzPCCq M1XwT2ROW09? MlLlTWM2OD15Lkmg{txO Mm\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUm5PVUoRjJ3NUm5PVk2RC:jPh?=
H460  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr1dHNwPy57IN88US=> MXiyOEBp Mk\1SG1UVw>? Mn3Gd4hwf3NiYTDyZYRqd3OnboPpeIl7cW6pIHXm[oVkfCC2bzDYMZJigXN? MkXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUm5PVUoRjJ3NUm5PVk2RC:jPh?=
NRK-52E NYCyfG1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Kz[VczyqCqwrC= NWnpT3FjUUN3ME2xNFAhyrFiMUKuPUDPxE1? Mn\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkW2NFMoRjJ3NU[1OlA{RC:jPh?=
RGE MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\TO|LDqGkEoB?= M4HFNGlEPTB;MkKgxtEhPy52IN88US=> MkTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkW2NFMoRjJ3NU[1OlA{RC:jPh?=
NRK-52E NITWU|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELGT5g4OsLiaNMg MVLJR|gxRTF5OTFCtUA6NjVizszN MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4NU[wN{c,OjV3NkW2NFM9N2F-
RGE NFTMdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jqPFczyqCqwrC= Ml7UTWM5OD14MzFCtUA4NjRizszN M3OwR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[1OlA{Lz5{NUW2OVYxOzxxYU6=
SK-OV-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTKO|IhcA>? Mo[yTWM2OD1zMESuPEDPxE1? NXXKSJdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
ES-2 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PHflczKGh? NH7UNXFKSzVyPUG0MlYh|ryP MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
OVCAR-8 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLzO|IhcA>? MVTJR|UxRTl4LkCg{txO MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
3AO NYHSXpdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTOO|IhcA>? M2G0d2lEPTB;NkOuOEDPxE1? NFXjNJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyNFE{Oid-MkW1NlAyOzJ:L3G+
A2780 NYHkZXAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PQZ|czKGh? NHvpTpNKSzVyPUG0OU44KM7:TR?= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
SW626 NFHPPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnSfGI4OiCq MWfJR|UxRTl5LkCg{txO M2LYZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
OVCAR-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3Dd2s4OiCq NEj3U5BKSzVyPUOyMlYh|ryP MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
A549 M1zSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF3MT61OkDDuSB3Mz6wOkDPxE1? NWnueGNVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
4T1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHETWM2OD16ND62NkDDuSB|MD6wOUDPxE1MIN88US=> M3nMcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
BALB/3T3 NWjleo1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojOTWM2OD1zND6zNEDDuSB4Lk[4JO69VQ>? MkTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
B16 NGnDVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfLRYhKSzVyPU[0MlMxKMLzIE[uPFEh|ryP NVrCeo8yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
DU 145 NV\4d2NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTN3LkC0JOKyKDF5LkW0JO69VQ>? M4L5bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
FaDu NY\tSHAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTR3LkO5JOKyKDFzLkWwJO69VQ>? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
HCV-29T NX25fGtpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\NT2lEPTB;NEiuOVchyrFiMkKuOFkh|ryP MmH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
HL-60 NXO2UJJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jlTmlEPTB;MUGuNVAhyrFiND60O{DPxE1? NInT[Wo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q3OSd-MkWyO|c1PjF:L3G+
HT-29 NWe5UnRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\6eWlEPTB;OEmuNVYhyrFiMUiuPFYh|ryP M4XKbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
H146 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfydo5xUUN3ME20PU43yrFzMz6xJO69VQ>? M1e0SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
H187 MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj5TWM2OD1zMj63xtEzNjdizszN NIj6OmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
H128 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFyNj60xtE6NjZizszN M1SxVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
H69 MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHleHBKSzVyPUe2MlnDuTJ5Lkig{txO MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H209 M3\pZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\lU493UUN3ME2yOVgvOcLzOUmuPEDPxE1? NGKxO3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
DMS153 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTieG5iUUN3ME21O{45yrF7LkKg{txO MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H526 M2fJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjmTWM2OD15LkNCtVEvPyEQvF2= M{\PR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
DMS114 NVjoeY5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7aNXN7UUN3ME24OU45yrFzMj64JO69VQ>? MlrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
DMS53 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr4TWM2OD1zNE[uNuKyOzZwNDFOwG0> M3j1[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
HeLa MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm5OWM2NThyIN88US=> MnrqbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MojtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzOlAoRjJ3MUC5N|YxRC:jPh?=
MCF-7 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvkOU05OCEQvF2= M1TqSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> Ml7mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzOlAoRjJ3MUC5N|YxRC:jPh?=
MDA-MB-231 NGTtRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnDcIY2PS16MDFOwG0> MXXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzOlAoRjJ3MUC5N|YxRC:jPh?=
CaOV3 NHvsc|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DUbFczKGh? NILTc5hKSzVyPUi2MlEh|ryP M{L5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
OVCAR-3 M333Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXPUXM4OiCq MkS3TWM2OD1zN{muOUDPxE1? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
OVCAR-5 NGTqO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DBNVczKGh? Mle0TWM2OD15NT63JO69VQ>? Mn3QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
SKOV-3 MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3GzdFczKGh? NUn5ZmhHUUN3ME21NFQh|ryP NYrjb5VERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlg5PDlpPkK1NFY5QDR7PD;hQi=>
OVCAR-4 MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;2b2s2PzJiaB?= MYXJR|UxRTJ7MD62JO69VQ>? NF74Olg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
OVCAR-8 M1nVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVi3NkBp NXLSZllWUUN3ME22PVAvOiEQvF2= NFXtcYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
MA148 M1vZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHKT3kzPCCq NHHLUpJKSzVyPUizMlbjiIoEsfMAjVEvPCEQvHevcYw> M4SwOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
A549 M1v1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXeyOEBp M4PMRWlEPTB;N{e2MlDjiIoEsfMAjVEvQSEQvHevcYw> M{DxbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MDA-MB-231 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Xh[lI1KGh? M3PYTWlEPTB;N{S4MlDjiIoEsfMAjVEvOSEQvHevcYw> M17oVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
NCI-ADR/RES  NH3GXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\nS3RZOjRiaB?= MnKzTWM2OD1zN{WzMlDjiIoEsfMAjVQvPCEQvHevcYw> NF7GcWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
MA148 NXnYV5lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPLNHZwPDhiaB?= NH;PUXVKSzVyPUK4MlHjiIoEsfMAjVEvOCEQvHevcYw> Mkm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
A549 NF\USoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPqOIFWPDhiaB?= MUnJR|UxRTFzOD6w5qCKyrIkgJmxMlIh|rypL33s MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
MDA-MB-231 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUS0PEBp MULJR|UxRTF6Mz6w5qCKyrIkgJmxMlIhKM7:Zz;tcC=> NFuwdVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
NCI-ADR/RES  Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3Tc4I1QCCq MkDwTWM2OD1zOUOuNQKBkcLz4pEJNU46KM7:Zz;tcC=> NFzmT|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
MA148 M3\Q[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDMbFQ4OiCq M{TvOGlEPTB;MUOuO-KBkcLz4pEJNU4zKM7:Zz;tcC=> NEDN[ZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
A549 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXTO|IhcA>? NGTmRnBKSzVyPU[0MlPjiIoEsfMAjVEvOSEQvHevcYw> MmL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
MDA-MB-231 NGXiS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW3NkBp M2XHdGlEPTB;OUmuOgKBkcLz4pEJNU4yKM7:Zz;tcC=> MmnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
NCI-ADR/RES  NHzOXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jBdVczKGh? NWLzVG1zUUN3ME2zO{416oDLwsJihKkyNjdizsznM41t NGG4Z3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
A549 NIfyUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLVO|IhcA>? MY\EUXNQ NYn3bXZSUUN3ME2xOVIvPDB7IN88US=> NXXsV4dRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlE{OjNpPkK0O|IyOzJ|PD;hQi=>
NCI-H157 NV;qdVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT4O|IhcA>? MVvEUXNQ Mn7WTWM2OD16OT65O|ch|ryP M1fzPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{KxN|I{Lz5{NEeyNVMzOzxxYU6=
PC9 NFmzO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnTe|VHPzJiaB?= NInnc4dISzVyPUexMlbDuTlwNTFCuW0> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzOEiwPUc,OjR4MUi4NFk9N2F-
A549  M3ywfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnudYRRPzJiaB?= M3fCbWdEPTB;MUO2xtE{OS54INM1UeKh NWG4WlBmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVg5ODlpPkK0OlE5QDB7PD;hQi=>
PC9 NFHPfIFCeG:ydH;zbZMhSXO|YYm= NV;l[mVHOTByINM1US=> MUm3NkBp NEjlTVlqdmS3Y3XzJIFxd3C2b4Ppdy=> NITnS3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[xPFgxQSd-MkS2NVg5ODl:L3G+
A549  MWfBdI9xfG:|aYOgRZN{[Xl? NYfqWlV4OTByINM1US=> NUnGc2FiPzJiaB?= NFTsfZpqdmS3Y3XzJIFxd3C2b4Ppdy=> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzOEiwPUc,OjR4MUi4NFk9N2F-
A549 NUSxbldjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[yOEBp NYe5VY8{UUNzME2xMlQ4PiCwTR?= M2LDb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m2OFM4Lz5{NEO5OlQ{PzxxYU6=
H1299 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLOUpgzPCCq M3;3fWlEOTB;MD60OFMhdk1? NHHTb4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5OlQ{Pyd-MkSzPVY1Ozd:L3G+
HCC15 NEHuWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\kSFczPCCq MV;JR|ExRTBwM{S2JI5O NYXIO|JRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N|k3PDN5PD;hQi=>
H157 M2W1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTnNlQhcA>? MWfJR|ExRTBwOEGgcm0> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7NkSzO{c,OjR|OU[0N|c9N2F-
A2780 NWi5b4pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\CTWM2OD1zND6w5qCKyrIkgJmxMlQh|ryP MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJyOU[5N{c,OjR{MEm2PVM9N2F-
A2780cisR NXPLfmo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTR6LkpihKnDueLCiUOuPUDPxE1? NFWxUmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+
A2780ZD0473R M1nRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fqemlEPTB;NkSuOwKBkcLz4pEJN{4zKM7:TR?= M17yPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=
SKOV-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP2TWM2OD12Mz605qCKyrIkgJmzMlkh|ryP M33LXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pChK-2 / Chk-2 ; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p38 / p38 / Cleaved PARP / PARP ; 

PubMed: 30049957     


A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋€𢡄�෋€䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemセ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄

30049957
Immunofluorescence
γH2AX ; 

PubMed: 24348048     


Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ

24348048
Growth inhibition assay
Cell viability ; 

PubMed: 24348048     


SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay. 

24348048
In vivo

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Dosages: ≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage 2 years 4°C(in the dark) powder
1 week 4°C(in the dark) in solvent
Synonyms JM-8, CBDCA, NSC 241240
Smiles C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04606914 Not yet recruiting Drug: mirvetuximab soravtansine (MIRV; IMGN853) Ovarian Cancer|Fallopian Tube|Primary Peritoneal Cancer University of Alabama at Birmingham March 31 2021 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID